Formulation Development and Evaluation of Sitagliptin PhosphateMonohydrate and Metformin HCl Tablets

Insulin resistance is actively treated with metformin. This drug improves insulin sensitivity and is essential for managingtype 2 diabetes. Glucose can treat diabetes alone if there are no safety concerns, such as renal or liver disease,gastrointestinal difficulties, or lactic acidosis. Metformin is safe and effective. Metformin is the only oral diabetes medicinethat does not cause weight gain. Additionally, many diabetics only take this medicine. Treatment for type 2 diabetes usuallybegins with metformin and sitagliptin. This helps manage blood sugar when diet and exercise fail. When administeredalone, sitagliptin plus metformin may not regulate blood glucose well. This aims to manufacture film-coated metforminphosphate monohydrate and hydrochloride tablets in various dosages. This study seeks to create a fixed dosepharmaceutical combination for non-insulin-dependent diabetic mellitus. Metformin HCl with Sitagliptin may improveblood sugar management and HbA1c levels. This combination causes minimal weight gain and fewer adverse effects. Thisstudy created and tested sitagliptin-metformin HCl film coated tablets. Wet granulation was used to make the tablets withthe requisite excipients. The tablet's parameters before and after compression were evaluated according to the standard.The pre-compression factors, including overall and tapped density, showed good flow characteristics. The weight,hardness, thickness, friability, disintegration, drug concentration, and drug release % were assessed after compression.Results showed these parameters were within acceptable ranges.